Form 4: Aurinia Pharmaceuticals Director Jill Leversage Reports Stock and Option Grants

Director Jill Leversage of Aurinia Pharmaceuticals reported the acquisition of restricted stock units and stock options.

Summary

• Jill Leversage, a director at Aurinia Pharmaceuticals, filed a Form 4 disclosing recent transactions.
• On November 21, 2024, Ms. Leversage was granted 12,135 restricted stock units (RSUs) which will vest one year from the grant date.
• She also received 18,641 stock options with an exercise price of $8.24, which also vest one year from the grant date and expire on November 21, 2034.
• Following these transactions, Ms. Leversage beneficially owns 25,053 common shares and 18,641 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard corporate practice of equity compensation for directors, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the director's interests with those of the shareholders.
• The vesting period of one year for both the RSUs and options encourages long-term commitment from the director.

Industry Context

This filing is a routine disclosure of equity grants to a company director, which is common practice in publicly traded companies to incentivize management and align their interests with shareholders.

Comparison to Industry Standards

• Equity grants to directors are a standard practice across the pharmaceutical industry.
• The vesting period of one year is also typical for such grants, aligning with industry norms for long-term incentives.
• The exercise price of $8.24 for the stock options is a common method to provide value to the director if the company's stock price increases.

Stakeholder Impact

• The equity grants align the director's interests with those of shareholders, potentially leading to better performance.
• The vesting period encourages long-term value creation for shareholders.

Key Dates

Keywords

Form 4, Aurinia Pharmaceuticals, Jill Leversage, stock options, restricted stock units, insider trading, beneficial ownership, equity compensation